Reported about 14 hours ago
As artificial intelligence reshapes the investing landscape in 2025, three biotech stocks stand out for their innovative approaches. AbbVie is leveraging AI in drug discovery to expedite development timelines; Gilead Sciences is enhancing its market position with successful antiviral therapies and partnerships for AI solutions; and Moderna, despite recent challenges, is using AI to explore new vaccine developments and aims for significant future growth. Together, these companies represent compelling investment opportunities in the evolving biotech sector.
Source: YAHOO